These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 24127257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
    Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT.
    J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
    [Abstract] [Full Text] [Related]

  • 3. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, Wagner A, van Der Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF.
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [Abstract] [Full Text] [Related]

  • 4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group.
    J Natl Cancer Inst; 2008 Nov 05; 100(21):1519-29. PubMed ID: 18957670
    [Abstract] [Full Text] [Related]

  • 5. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H.
    JAMA; 1996 Jun 26; 275(24):1885-92. PubMed ID: 8648868
    [Abstract] [Full Text] [Related]

  • 6. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD.
    Oncol Nurs Forum; 2011 Sep 26; 38(5):572-81. PubMed ID: 21875844
    [Abstract] [Full Text] [Related]

  • 7. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.
    J Natl Cancer Inst; 2004 Jul 21; 96(14):1094-8. PubMed ID: 15265971
    [Abstract] [Full Text] [Related]

  • 8. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W.
    J Clin Oncol; 2006 Aug 01; 24(22):3672-7. PubMed ID: 16877736
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
    Halbert CH, Wenzel L, Lerman C, Peshkin BN, Narod S, Marcus A, Corio C, Demarco T, Bellamy S.
    Cancer Epidemiol Biomarkers Prev; 2004 May 01; 13(5):875-81. PubMed ID: 15159322
    [Abstract] [Full Text] [Related]

  • 12. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
    Vos J, Menko FH, Oosterwijk JC, van Asperen CJ, Stiggelbout AM, Tibben A.
    Psychooncology; 2013 May 01; 22(5):1167-76. PubMed ID: 22777929
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Gomez Garcia E, Tibben A.
    Psychooncology; 2013 Apr 01; 22(4):902-10. PubMed ID: 22740372
    [Abstract] [Full Text] [Related]

  • 16. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J, Itzen M, Malick J, Babb JS, Bove B, Godwin AK, Daly MB.
    Am J Med Genet C Semin Med Genet; 2003 May 15; 119C(1):11-8. PubMed ID: 12704633
    [Abstract] [Full Text] [Related]

  • 17. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.
    Gynecol Oncol; 2000 Sep 15; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women's looking back on the pre-test period and a psychological evaluation.
    Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E.
    Genet Test; 2004 Sep 15; 8(1):13-21. PubMed ID: 15140370
    [Abstract] [Full Text] [Related]

  • 19. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M, Frydman M, Friedman I, Shiri-Sverdlov R, Papa MZ, Goldman B, Friedman E.
    Am J Med Genet; 2002 Aug 01; 111(2):147-51. PubMed ID: 12210341
    [Abstract] [Full Text] [Related]

  • 20. Identification of patients at high risk of psychological distress after BRCA1 genetic testing.
    Ertmański S, Metcalfe K, Trempała J, Głowacka MD, Lubiński J, Narod SA, Gronwald J.
    Genet Test Mol Biomarkers; 2009 Jun 01; 13(3):325-30. PubMed ID: 19405874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.